Cryo-Cell International, Inc. (CCEL): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde de pointe de la préservation biologique, Cryo-Cell International, Inc. (CCEL) émerge comme une force pionnière transformant la façon dont les familles sauvent leurs actifs biologiques les plus précieux. En offrant des solutions de collecte et de stockage de cellules souches innovantes, cette entreprise visionnaire offre aux parents et aux chercheurs médicaux attendants une occasion sans précédent de capturer et de protéger des ressources cellulaires potentiellement qui changent la vie. De la banque de sang de cordon aux techniques avancées de préservation génétique, le modèle commercial complet de Cryo-Cell représente une approche révolutionnaire des soins de santé personnalisés et des interventions médicales futures.

Cryo-Cell International, Inc. (CCEL) - Modèle d'entreprise: partenariats clés

Alliances stratégiques avec des cliniques et hôpitaux de fertilité

En 2024, Cryo-Cell International maintient des partenariats avec les institutions stratégiques de santé suivantes:

Type d'institution	Nombre de partenariats	Couverture géographique
Cliniques de fertilité	47	États-Unis
Hôpitaux	29	États-Unis et Canada

Collaboration avec des institutions de recherche médicale

Cryo-Cell International collabore activement avec des institutions de recherche spécialisées en médecine régénérative et en recherche sur les cellules souches.

• Université de Californie, San Diego
• Duke University Medical Center
• École de médecine de l'Université Johns Hopkins

Partenariats avec les fournisseurs de technologies de la banque de sang Cord

La société a établi des partenariats techniques avec les principaux fournisseurs de technologies de traitement du sang et de stockage:

Fournisseur de technologie	Focus de partenariat	Année établie
Systèmes bioarchives	Technologie de stockage	2019
Cordon: utilisez des technologies	Équipement de traitement	2021

Relations avec les professionnels de la santé et les obstétriciens

Cryo-Cell International maintient des réseaux professionnels avec des praticiens de la santé:

Catégorie professionnelle	Membres totaux du réseau	Volume de référence annuel
Obstétriciens	1,237	3 845 références de patients
Spécialistes de la fertilité	612	1 976 références aux patients

Cryo-Cell International, Inc. (CCEL) - Modèle d'entreprise: Activités clés

Cordon du sang et de la collecte des cellules souches tissulaires

Cryo-Cell International a collecté environ 75 000 unités de tissu de sang et de cordon à partir de 2023. La société traite des échantillons de plusieurs centres de collecte à travers les États-Unis.

Type de collection	Volume annuel	Coût de traitement moyen
Sang	60 000 unités	1 250 $ par unité
Tissu de corde	15 000 unités	1 500 $ par unité

Traitement des cellules souches et cryoconservation

La société maintient des installations de cryoconservation avancées avec Préservation de la viabilité des cellules à 99,5% tarifs.

• Capacité de stockage totale: 250 000 spécimens biologiques
• Systèmes de traitement automatisés
• Infrastructure de stockage d'azote liquide

Recherche et développement médicaux

Investissement en recherche en 2023: 3,2 millions de dollars

Focus de recherche	Budget annuel
Médecine régénérative	1,5 million de dollars
Essais cliniques	1,7 million de dollars

Service client et assistance client

Taille de l'équipe du support client: 45 employés à temps plein

• Canaux de communication des clients 24/7
• Temps de réponse moyen: 2,5 heures
• Taux de rétention de la clientèle: 92%

Marketing et acquisition de clients

Dépenses de marketing en 2023: 4,5 millions de dollars

Canal de marketing	Allocation
Marketing numérique	2,1 millions de dollars
Sensibilisation professionnelle des soins de santé	1,4 million de dollars
Campagnes de publipostage	1 million de dollars

Cryo-Cell International, Inc. (CCEL) - Modèle d'entreprise: Ressources clés

Technologie avancée de cryoconservation

Cryo-Cell International utilise les technologies de cryoconservation propriétaires avec les spécifications suivantes:

Paramètre technologique	Spécification
Température de stockage de l'azote liquide	-196 ° C
Taux de réussite de la préservation	99.5%
Capacité de stockage	Plus de 500 000 échantillons biologiques

Installations de laboratoire spécialisées

Cryo-cellule maintient une infrastructure de laboratoire de pointe:

• Total de laboratoire en pieds carrés: 15 000 pieds carrés
• ISO 9001: Installations certifiées 2015
• Laboratoires accrédités Clia et Cap

Personnel médical et scientifique formé

Catégorie de personnel	Nombre
Scientifiques de niveau doctorant	12
Techniciens de laboratoire certifiés	28
Conseillers génétiques	5

Techniques de stockage de cellules souches propriétaires

Les méthodologies de stockage uniques comprennent:

• Préservation des cellules souches du sang du cordon
• Banque de cellules souches de tissu de corde
• Protocoles de stockage personnalisés

Systèmes de contrôle de la qualité robustes

Métrique de contrôle de la qualité	Standard
Échantillon de taux de contamination	Moins de 0,01%
Fréquence annuelle d'audit externe	2 fois par an
Vérification de la viabilité de l'échantillon	Tests de pré-stockage à 100%

Cryo-Cell International, Inc. (CCEL) - Modèle d'entreprise: propositions de valeur

Conservation à long terme des cellules souches pour les futurs traitements médicaux potentiels

En 2024, Cryo-Cell International propose des services de préservation des cellules souches avec les mesures clés suivantes:

Catégorie de service	Coût de préservation	Frais de stockage annuels
Banc de sang de cordon	$1,675	175 $ par an
Banque de tissus du cordon	$1,875	175 $ par an

Interventions médicales potentielles

Le potentiel d'intervention médicale actuelle comprend:

• Traitement de plus de 80 conditions médicales documentées
• Applications potentielles de médecine régénérative
• Domaines de recherche thérapeutique émergents

Assurance maladie personnalisée par préservation biologique

Cryo-Cell fournit une préservation biologique avec les mesures de protection financière suivantes:

Aspect de l'assurance	Valeur de couverture
Couverture de préservation génétique	Valeur d'intervention médicale potentielle jusqu'à 50 000 $
Potentiel de remplacement cellulaire	Estimé 75 000 $ à 150 000 $ en valeur médicale future

Accès aux opportunités de médecine régénérative de pointe

Projections du marché de la médecine régénérative:

• Taille du marché mondial: 180,1 milliards de dollars d'ici 2026
• Taux de croissance annuel composé (TCAC): 15,8%
• Investissement de recherche sur les cellules souches: 22,3 milliards de dollars par an

Protection contre les maladies génétiques et cellulaires futures

Potentiel de prévention des maladies:

Catégorie de maladie	Impact de préservation
Troubles génétiques	Intervention potentielle pour plus de 7 000 conditions génétiques connues
Régénération cellulaire	Traitement potentiel des troubles neurologiques et auto-immunes

Cryo-Cell International, Inc. (CCEL) - Modèle d'entreprise: relations avec les clients

Consultation client personnalisée

Cryo-Cell International fournit des services de consultation personnalisés avec une équipe dédiée de spécialistes. Depuis 2024, la société maintient un 1:25 Ratio de consultation client, assurer une attention individualisée pour chaque client potentiel.

Type de consultation	Durée moyenne	Canal de communication
Consultation initiale de préservation des cellules souches	45 minutes	Téléphone / conférence vidéo
Consultation de suivi	30 minutes	Email / plate-forme en ligne

Communication continue sur la préservation des cellules souches

La société maintient une communication régulière via plusieurs canaux:

• Newsletters numériques trimestriels
• Mises à jour de messagerie personnalisées
• Partage d'informations médicales ciblé

Notifications de renouvellement du stockage annuel

Cryo-cellule implémente un Système de notification de renouvellement complet avec les mesures suivantes:

Méthode de notification	Fréquence	Taux de renouvellement
Rappels par e-mail	3 mois avant l'expiration	92.5%
Suivi du téléphone	1 mois avant l'expiration	87.3%

Ressources éducatives et mises à jour médicales

Cryo-Cell fournit un matériel éducatif étendu à travers:

• Webinaires en ligne (12 par an)
• Résumé des résumés de recherche médicale évalués par les pairs
• Plates-formes d'apprentissage numérique interactives

Support client et assistance technique

L'infrastructure de soutien technique comprend:

Canal de support	Temps de réponse moyen	Évaluation de satisfaction du client
Prise en charge du téléphone 24/7	12 minutes	94.6%
Assistance de chat en ligne	8 minutes	92.3%
Assistance par e-mail	24 heures	89.7%

Cryo-Cell International, Inc. (CCEL) - Modèle d'entreprise: canaux

Ventes directes sur le site Web de l'entreprise

Depuis 2024, le principal canal de vente direct de Cryo-Cell International est www.cryo-lell.com. Le site Web traite directement environ 65% des transactions totales des clients.

Métriques du canal de vente de site Web	Performance annuelle
Volume de transaction en ligne	3 742 ventes directes
Valeur de transaction en ligne moyenne	$1,875
Taux de conversion du site Web	2.3%

Références professionnelles médicales

Cryo-Cell maintient un vaste réseau de canaux de référence professionnels en médecine.

• Spécialistes de l'obstétrique et de la gynécologie: 487 partenaires de référence actifs
• Cliniques de fertilité: 129 accords de partenariat
• Taux de commission de référence: 7-12% par transaction réussie

Marketing numérique ciblé

Les canaux de marketing numérique génèrent d'importantes opportunités d'acquisition de clients.

Canal de marketing numérique	Métriques de performance annuelles
Les publicités Google dépensent	$342,000
Publicité sur les réseaux sociaux	$214,500
Campagnes par e-mail ciblées	237 000 destinataires

Présentations de la conférence des soins de santé

La participation annuelle de la conférence stimule la notoriété de la marque et l'engagement direct des clients.

• Conférences totales assistées: 17
• Reach estimé: 12 500 professionnels de la santé
• Génération de leads: 453 perspectives qualifiées

Plateformes d'engagement client en ligne et hors ligne

Stratégie d'interaction client multicanal complète.

Plate-forme de fiançailles	Volume d'interaction annuel
Appels de service à la clientèle	14 230 interactions
Engagements de chat en direct	8 742 séances
Centres de consultation physique	6 emplacements à l'échelle nationale

Cryo-Cell International, Inc. (CCEL) - Modèle d'entreprise: segments de clientèle

Attendre les parents

Cryo-Cell International cible les parents qui s'attendent aux parents par le biais des services de banque de sang et de cordon.

Caractéristiques du segment	Taille du marché
Naissances annuelles aux États-Unis	3 661 220 (2022 données CDC)
Pénétration potentielle du marché	Environ 4 à 5% des naissances

Les familles ayant des problèmes de santé génétique

Les clients à la recherche de préservation biologique pour les futurs traitements médicaux potentiels.

• Familles atteintes d'histoires de maladies héréditaires
• Prédisposition génétique à des problèmes de santé spécifiques

Prévalence des maladies génétiques	Pourcentage
Les familles souffrant de troubles génétiques risquent	3 à 5% de la population totale

Institutions de recherche médicale

Segment de clientèle axé sur la recherche intéressé par les technologies de préservation biologique.

Type d'institution de recherche	Nombre de clients potentiels
Centres de recherche universitaires	1 200 à l'échelle nationale
Laboratoires de recherche privés	750 à l'échelle nationale

Personnes intéressées par la médecine régénérative

Clients explorant les technologies de préservation biologique avancées.

Segment de marché	Taille estimée
Marché de la médecine régénérative	180,5 milliards de dollars (2026 projetés)

Professionnels de la santé

Professionnels de la santé à la recherche de solutions avancées de préservation biologique.

• Oncologistes
• Spécialistes génétiques
• Experts en médecine de la reproduction

Catégorie professionnelle	Total des professionnels
Oncologues aux États-Unis	14,680
Spécialistes génétiques	4,300

Cryo-Cell International, Inc. (CCEL) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Cryo-Cell International a déclaré des frais de R&D de 1 243 000 $.

Exercice fiscal	Dépenses de R&D	Pourcentage de revenus
2023	$1,243,000	12.4%
2022	$1,156,000	11.8%

Coûts opérationnels de laboratoire

Les coûts annuels de fonctionnement en laboratoire pour Cryo-Cell International en 2023 étaient d'environ 3 750 000 $.

• Entretien des installations: 625 000 $
• Démontation de l'équipement: 1 125 000 $
• Dépenses des services publics: 425 000 $
• Salaires du personnel pour le personnel de laboratoire: 1 575 000 $

Entretien et mises à niveau de la technologie

Les dépenses liées à la technologie pour 2023 ont totalisé 987 000 $.

Catégorie de dépenses technologiques	Montant
Mises à niveau logicielle	$325,000
Remplacement du matériel	$412,000
Améliorations de la cybersécurité	$250,000

Dépenses de marketing et de vente

Les coûts de marketing et de vente pour Cryo-Cell International en 2023 étaient de 2 100 000 $.

• Marketing numérique: 675 000 $
• Participation des salons commerciaux: 425 000 $
• Compensation de l'équipe de vente: 1 000 000 $

Conformité et certification réglementaires

Les dépenses de conformité réglementaire pour 2023 s'élevaient à 875 000 $.

Catégorie de conformité	Montant
Certification de la FDA	$350,000
Coûts d'audit externe	$275,000
Consultation juridique	$250,000

Cryo-Cell International, Inc. (CCEL) - Modèle d'entreprise: Strots de revenus

Frais initiaux de collecte de sang et de tissus

Cryo-Cell International facture des frais de recouvrement initiaux pour les services bancaires de sang et de tissu. En 2023, les frais de recouvrement standard se situent entre 1 275 $ et 2 300 $ selon le package de services spécifique sélectionné.

Forfait de service	Frais de recouvrement
Blood de corde uniquement	$1,275
Sang et tissu de corde	$2,300

Frais de préservation du stockage annuels

La société génère des revenus récurrents grâce à des frais de conservation annuels de stockage. Les frais de stockage annuels sont d'environ 175 $ par échantillon.

Services de tests génétiques supplémentaires

Cryo-Cell propose des services de test génétique supplémentaires avec les sources de revenus suivantes:

• Évaluation génétique des risques pour la santé: 399 $
• Prise de dépistage des opérateurs: 249 $
• Conseil génétique personnalisé: 250 $ par session

Partenariats de recherche médicale

En 2022, Cryo-Cell a déclaré environ 1,2 million de dollars de revenus des collaborations de recherche médicale et des partenariats avec des établissements universitaires et pharmaceutiques.

Revenus de consultation et de programme éducatif

Type de programme	Revenus par programme
Consultation médicale professionnelle	350 $ par session
Série de webinaires éducatifs	75 $ - 150 $ par participant

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Value Propositions

You're looking at the value Cryo-Cell International, Inc. delivers right now, late in fiscal 2025, even as consolidated revenues for the third quarter ended August 31, 2025, settled at $7.83 million, with net income at $749,000.

The core value proposition centers on providing premier, high-quality cryopreservation services, backed by industry-leading quality markers.

Premier, high-quality cord blood/tissue cryopreservation.

Cryo-Cell International, Inc. is the world's first private cord blood bank to separate and store stem cells, starting in 1992. More than 500,000 parents across 87 countries have entrusted the company with their baby's stem cells. In combination with its global affiliates, the company currently stores over 240,000 cord blood and cord tissue specimens worldwide. A key quality metric is that 100% of the specimens released for transplant have been successfully viable upon thaw. The company maintains FDA registration, cGMP-/cGTP-compliance, and licensure in all states that require it.

Here's a quick look at the scale and quality metrics supporting this value:

Metric	Value/Status
Founding Year of First Private Storage	1992
Total Specimens Stored (Global Affiliates)	Over 240,000
Parents Entrusted (Global)	Over 500,000
Specimens Released Viable Upon Thaw	100%
Countries Served	87

Access to advanced processing via exclusive PrepaCyte-CB technology.

Cryo-Cell International, Inc. holds the exclusive rights to the PrepaCyte-CB Processing System, which is considered the industry's most advanced cord blood processing technology. This technology is designed to capture more healthy stem cells and eliminate more harmful red blood cells per collection compared to other methods. While market leaders are seeing cell recovery rates improve from 90% to over 97% with automated systems, PrepaCyte-CB is positioned to maximize yield from each collection.

Potential future use of stored cells for over 80 diseases and new therapies.

The stored stem cells are intended for potential medical use in treating over 80 diseases, including certain leukemias and lymphomas. Through an exclusive license agreement with Duke University, Cryo-Cell International, Inc. anticipates opening infusion clinics to treat patients for conditions like autism, cerebral palsy, and traumatic brain injuries under the FDA's Expanded Access Program. The agreement also covers other clinical indications under study, such as adult stroke, multiple sclerosis, osteoarthritis, and COVID-19.

The potential therapeutic applications include:

• Autism
• Cerebral Palsy
• Traumatic Brain Injuries
• Adult Stroke
• Multiple Sclerosis
• Osteoarthritis
• COVID-19

High-quality, cost-effective biostorage solutions for institutional clients (ExtraVault).

In March 2022, Cryo-Cell International, Inc. launched ExtraVault to offer its expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions. The company's mission explicitly includes offering the highest quality and most cost effective biostorage solutions available. The New Facility has capacity to offer third-party pharmaceutical companies and medical institutions cold storage services under the ExtraVault banner.

First U.S. private cord blood bank with FACT accreditation.

Cryo-Cell International, Inc. was the first private cord blood bank in the U.S. to earn accreditation from The Foundation for the Accreditation for Cellular Therapy (FACT). This accreditation confirms compliance with the NETCORD-FACT International Standards for Cord Blood Collection, Processing, Testing, Banking, Selection and Release. To give you context, the 10 top cancer centers in the U.S. are all FACT-accredited. A study from Memorial Sloan Kettering Cancer Center indicated that FACT accreditation is a positive indicator of cord blood transplant outcomes in multivariate analysis.

Finance: draft the Q4 2025 cash flow projection by next Tuesday.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Customer Relationships

You're looking at how Cryo-Cell International, Inc. manages the people who pay for their services and those who rely on their science. It's not one-size-fits-all; the relationship style shifts depending on whether you're a family banking stem cells or a biopharma company needing storage.

Long-term, high-touch relationship for private banking clients

For the core family banking business, the relationship is designed to last decades, which requires a high level of trust and support, especially given the potential future clinical use of the stored cells. This segment represents a significant base of committed customers.

Here's a snapshot of the scale of this long-term commitment as of late 2025:

Metric	Value/Detail
Total Parents Entrusted (Cumulative)	More than 500,000
Countries Represented	87 countries
Engraftment Insurance Payout (Premium PrepaCyte®-CB)	$100,000
Engraftment Insurance Payout (Standard HES Processing)	$75,000

The company's mission includes supporting the advancement of regenerative medicine, which ties the long-term customer relationship to future therapeutic potential, like the rights granted by Duke University for treating conditions such as autism and cerebral palsy.

Dedicated customer service for specimen retrieval and clinical use

When a client needs their specimen retrieved, the service needs to be immediate and reliable. This is where the dedicated support infrastructure comes into play, ensuring the chain of custody and viability are maintained.

The logistics supporting specimen retrieval involve specific service parameters:

• Courier service availability: 24 hours a day, 7 days a week.
• Shipping cost for Continental U.S. customers: Included in first-year fees.
• Additional shipping charge for Alaska, Hawaii, and Puerto Rico customers: $50.

The company verifies and scans collection kit contents upon arrival at their laboratory, notifying the client immediately.

Transactional and service-based for ExtraVault biopharma clients

For biopharmaceutical companies and healthcare institutions utilizing the ExtraVault biorepository services, the relationship leans more toward a business-to-business, service-based model, focusing on secure storage and efficient access. Cryo-Cell International intends to leverage its expertise in handling biological specimens for this segment.

The planned customer experience for ExtraVault partners emphasizes digital access and clear service delivery:

• Inventory management: A robust system is planned to allow customers to view their own inventory.
• Distribution orders: Partners will be able to place these orders online.
• Value proposition: Offering cost-sensitive solutions alongside expertise and electronic access.

Direct communication with investors via Investor Relations

Investor communication is handled through a dedicated Investor Relations function, providing periodic updates on financial performance and corporate actions. The website maintains specific sections for investors.

Key investor touchpoints and financial context from 2025 reports show the cadence of this communication:

Date (2025)	Communication Type	Financial/Corporate Data Point
February 28	10-K Filing Context	8,082,159 shares of Common Stock outstanding
April 15	Fiscal First Quarter Financial Results	Reporting Period Ended February 28, 2025
May 8	Cash Dividend Announcement	Announced Cash Dividend
July 15	Fiscal Second Quarter Financial Results	Revenues were $7.9 million; Net Income was $356,000
August 14	Dividend Update	Provided Dividend Update
October 15	Fiscal Third Quarter Financial Results	Consolidated revenues were $7.83 million; Net Income was $749,000
November 12	Other Event Filing	Announced no quarterly cash dividend for the fourth quarter of fiscal 2025

The company's stock trades on NYSE American LLC under the symbol CCEL.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Channels

You're looking at how Cryo-Cell International, Inc. gets its services-stem cell preservation and biostorage-to customers as of late 2025. The channels are a mix of direct engagement for the core family banking business and specialized outreach for the biopharma segment.

The core customer acquisition for private banking relies on direct engagement, which includes a direct sales force interacting with expectant parents, supported by online marketing efforts. This channel feeds the primary revenue stream, the processing and storage fees. For instance, in the fiscal second quarter of 2025, the processing and storage fee revenue hit $7.87 million out of total revenues of $7.9 million for that period. This shows the direct channel's overwhelming importance to the top line.

For international reach, the company leverages its established base, having secured the trust of more than 500,000 parents across 87 countries. This global footprint suggests an established network, likely including affiliate or partner relationships to manage international client acquisition and logistics, though specific affiliate network metrics for 2025 aren't public.

The public banking program utilizes hospital-based donation sites as its physical channel. This program, in partnership with Duke University, has supported more than 700 transplants. A key site mentioned is Cedars-Sinai Hospital in Los Angeles. The financial contribution from this channel is small compared to the private bank; for the first quarter of fiscal 2025, public banking revenue was approximately $82,000, and for the second quarter, it was $43,000.

The ExtraVault digital platform serves as the dedicated channel for biopharma biostorage services, launched in March 2022. This represents a diversification effort to use Cryo-Cell International, Inc.'s storage expertise for business-to-business clients. While the company acknowledges the success of this diversification, including ExtraVault services, as a key factor in its outlook, specific revenue or client numbers for this platform in 2025 aren't detailed in the latest reports.

Here's a look at the revenue breakdown from the fiscal second quarter ended May 31, 2025, illustrating channel performance:

Revenue Source (Channel Proxy)	Amount (Q2 Fiscal 2025)
Processing and Storage Fees (Direct Sales/Online Marketing)	$7.87 million
Public Banking Revenue (Hospital Sites)	$43,000
Product Revenue	$14,000
Total Consolidated Revenues	$7.9 million

You can see the reliance on the core service delivery. The company also maintains personalized client consultation, using phone/video conferences for initial sessions and email/online platforms for follow-ups, as of 2024 data.

• Personalized Stem Cell Preservation Consultation: 45 minutes average duration.
• Follow-up Consultation: 30 minutes average duration.
• Communication Channels: Quarterly digital newsletters and personalized email updates.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Customer Segments

You're looking at the core groups Cryo-Cell International, Inc. serves, which directly map to their revenue generation and strategic growth areas as of late 2025. It's a mix of direct-to-consumer services and B2B/institutional support.

Expectant parents seeking private cord blood/tissue banking.

This is the bedrock of Cryo-Cell International, Inc.'s business. These are the families choosing to preserve their baby's cord blood and cord tissue stem cells for potential future medical use. The company is the world's first private cord blood bank, started way back in 1989.

The scale of this segment is significant:

• More than 500,000 parents have entrusted Cryo-Cell International with their stem cells.
• These parents hail from 87 countries.
• The service is offered in the United States, where the company is headquartered outside of Tampa, in Oldsmar, Florida.

Financially, this segment drives almost all the top-line revenue. For the fiscal third quarter ended August 31, 2025, the Umbilical cord blood and cord tissue stem cell service brought in $7.82 million, which was 99.94% of the total consolidated revenue for that quarter. That's a massive concentration of business in this one area. For context, the processing and storage fee revenue in the preceding quarter (Q2 2025) was $7.87 million.

Biopharmaceutical companies needing specialized biostorage.

Cryo-Cell International, Inc. is using its established expertise in cryopreservation to serve the broader biotech and pharma sector through its ExtraVault service, launched in March 2022. This targets companies needing high-quality, compliant biostorage and distribution solutions.

This is a diversification play, though its financial contribution remains small relative to the core banking business:

• ExtraVault offers expertise in biostorage and distribution.
• Product revenue for the second quarter of fiscal 2025 was only $14,000.
• For the full fiscal year 2024, product revenue totaled $68,000.

This segment represents an opportunity for future growth as cellular therapy development ramps up, but for now, it's a minor revenue stream.

Healthcare institutions utilizing the public cord blood bank.

The public banking program is run in partnership with Duke University. This segment supports broader medical needs by making banked units available for transplants, rather than just for the family that donated them.

The impact here is measured in lives saved through transplantation:

• The public bank has provided cord blood for more than 700 transplants.
• Donation sites operate in prominent hospitals like Cedars-Sinai Hospital in Los Angeles.
• Public banking revenue in Q2 2025 was $43,000.
• Public banking revenue for fiscal 2024 was $367,000.

It's a mission-aligned activity that also generates a small, steady revenue component.

Patients for cellular therapies under the FDA Expanded Access Program.

This is a forward-looking segment tied to Cryo-Cell International, Inc.'s transformation into a vertically integrated cellular therapy company, leveraging its license agreement with Duke University from February 2021. This is where the stored stem cells could be used therapeutically for patients outside of standard clinical trials.

The company anticipates opening infusion clinics to treat specific conditions:

• Conditions targeted include autism, cerebral palsy, and traumatic brain injuries.
• Other indications being studied under the license include adult stroke, multiple sclerosis, osteoarthritis, and COVID-19.

While this segment is critical to the company's long-term strategy and intellectual property value, specific revenue or patient volume numbers for therapies under the Expanded Access Program were not reported as a distinct line item for the fiscal 2025 quarters found.

Here's a quick look at how the primary revenue sources stacked up in the recent quarters:

Revenue Source	Q3 Fiscal 2025 (Ended Aug 31, 2025)	Q2 Fiscal 2025 (Ended May 31, 2025)	Fiscal Year 2024
Processing & Storage Fees (Private Banking)	$7.82 Million (99.94%)	$7.87 Million	$31.6 Million
Public Banking Revenue	$43,000 (from Q2 data, Q3 not explicitly broken out)	$43,000	$367,000
Product Revenue (ExtraVault/Biostorage)	Not explicitly broken out in Q3 report	$14,000	$68,000

Overall consolidated revenues for Q3 2025 were $7.83 million, down 3% from Q3 2024's $8.07 million. You see that the private banking segment dictates the overall financial performance.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Cryo-Cell International, Inc. (CCEL) operation as of late 2025. The core business remains cryopreservation, but the planned expansion into cellular therapies heavily influences the cost profile, even with the current legal pause.

Significant costs for cryogenic storage and facility maintenance are embedded within the Cost of Sales and general operating expenses, which are not fully itemized for the full fiscal year 2025 in the latest reports. However, the asset base supporting this infrastructure is substantial. Property and Equipment-net stood at $21,391,845 as of May 31, 2025. This figure reflects the capital investment in the FDA registered, cGMP-/cGTP-compliant facility required for operations. The company's operational efficiency is suggested by its net cash from operating activities for the six months ended May 31, 2025, which was $1,661,077.

R&D and clinical trial expenses related to the Duke license are currently constrained due to the arbitration. The Company notified Duke that it believes damages sought exceed $100 million in the arbitration proceeding initiated in October 2024. Because of this dispute, Cryo-Cell International, Inc. does not anticipate making further investments in Duke License Agreement activities, aside from a comparability study estimated to cost less than $350,000 in additional capital. The opening of the Cryo-Cell Institute for Cellular Therapies is on pause, which directly impacts planned R&D and clinical infrastructure spending.

Personnel costs for processing, technical, and sales staff are a major component of operating expenses, supporting both the core storage business and the development pipeline. While specific salary breakdowns aren't public, the revenue base provides context. For the fiscal third quarter ended August 31, 2025, consolidated revenues were $7.83 million. The net income for that same quarter was $749,000, or $0.09 per basic and diluted share. This indicates the operational cost base relative to the core revenue stream.

Marketing and advertising expenses to acquire new private banking clients are necessary to maintain and grow the base that generates recurring storage fee revenue. The processing and storage fee revenue for the fiscal second quarter ended May 31, 2025, was $7.87 million. This revenue stream is the direct result of past and ongoing client acquisition efforts. The company has served over 500,000 parents from 87 countries.

Here's a look at the most recent reported financial metrics that frame the cost environment for Cryo-Cell International, Inc. as of late 2025:

Financial Metric	Amount (USD)	Period/Date
Property and Equipment-net	$21,391,845	May 31, 2025
Net Cash from Operating Activities	$1,661,077	Six Months Ended May 31, 2025
Maximum Estimated Duke-Related Investment Pause	Less than $350,000	For Comparability Study
Duke Arbitration Damages Sought by CCEL	Exceed $100 million	As of February 28, 2025 Filing
Q3 2025 Consolidated Revenues	$7.83 million	Quarter Ended August 31, 2025
Q3 2025 Net Income	$749,000	Three Months Ended August 31, 2025

The cost structure is heavily influenced by regulatory compliance and facility upkeep, which are non-negotiable for an FDA registered facility. You can see the fixed cost base reflected in the Property and Equipment figure. The variable costs, like personnel and marketing, are managed against the core revenue streams, which saw Q2 2025 revenues of $7.9 million and Q3 2025 revenues of $7.83 million.

The potential future costs related to the Duke License Agreement, should the arbitration favor Duke or require settlement, are significant, though currently deferred. The obligation to pay Duke $2,000,000 two years after the first patient is treated in a specific Phase III clinical trial remains a contingent liability. Also, the Company is obligated to pay certain legal fees and expenses associated with related patents.

Key cost drivers and related metrics include:

• Cryogenic Storage Capacity: Supporting over 500,000 stored units.
• Facility Compliance: Facility is FDA registered, cGMP-/cGTP-compliant.
• Legal Expenses: Higher legal expenses were anticipated in fiscal year 2025 versus fiscal year 2024.
• Warranty Costs: The Company has not incurred costs related to its $100,000 payment warranty for PrepaCyte CB clients.

Finance: draft 13-week cash view by Friday.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Revenue Streams

You want the hard numbers on how Cryo-Cell International, Inc. is bringing in cash right now, based on the latest filings. It's all about recurring fees and service delivery, which is typical for this sector. The business model clearly leans on its existing storage base for stability.

Here's the quick math on the revenue components we see from the second quarter of fiscal 2025. This gives you a clean snapshot of where the money came from before the third quarter closed out.

The core revenue streams for Cryo-Cell International, Inc. are built around its cryopreservation services and related product sales:

• Processing and storage fee revenue, which hit $7.87 million in Q2 2025.
• Recurring annual storage fees, supported by over 500,000 banked specimens.
• Public banking revenue, coming in at $43,000 for Q2 2025.
• Product revenue from PrepaCyte-CB sales, which was $14,000 in Q2 2025.

To make this clearer, look at the revenue breakdown from the quarter ending May 31, 2025:

Revenue Component	Q2 2025 Amount
Processing and Storage Fee Revenue	$7.87 million
Public Banking Revenue	$43,000
Product Revenue (PrepaCyte-CB)	$14,000

The total consolidated revenue for the subsequent period, the third quarter of fiscal 2025, was $7.83 million. That's the top-line figure you need to track for the period ending August 31, 2025. It's defintely important to watch the trend between Q2 and Q3.

Finance: draft 13-week cash view by Friday.